Compare · PXDT vs SLNO
PXDT vs SLNO
Side-by-side comparison of Pixie Dust Technologies Inc. (PXDT) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PXDT and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO carries a market cap of $2.76B.
- SLNO has hit the wire 39 times in the past 4 weeks while PXDT has been quiet.
- SLNO has more recent analyst coverage (12 ratings vs 0 for PXDT).
- Company
- Pixie Dust Technologies Inc.
- Soleno Therapeutics Inc.
- Price
- -
- -
- Market cap
- -
- $2.76B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- 2014
- News (4w)
- 0
- 39
- Recent ratings
- 0
- 12
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest PXDT
- SEC Form 6-K filed by Pixie Dust Technologies Inc.
- Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.
- Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.
- Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.
- Amendment: SEC Form SC 13D/A filed by Pixie Dust Technologies Inc.
- Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.
- SEC Form 25 filed by Pixie Dust Technologies Inc.
- /C O R R E C T I O N -- Pixie Dust Technologies/
- Amendment: SEC Form 6-K/A filed by Pixie Dust Technologies Inc.
- Notice regarding Plan to Delist American Depositary Receipts from NASDAQ Capital Market and Deregister with U.S. Securities and Exchange Commission.
Latest SLNO
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Manning Meredith returned 64,507 shares to the company, closing all direct ownership in the company (SEC Form 4)